EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Patient-reported oral adverse events during cancer chemotherapy: longitudinal evaluation using patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE) and concordance with clinician assessments

Yuki Sakai, Kouji Katsura, Yoshitomi Kanemitsu, Masaaki Kotake, Akira Toyama

Supportive Care in Cancer · 2025

DOI: 10.1007/s00520-025-10126-3 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Supportive Care in Cancer, 2025. Verfasst von Yuki Sakai und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Niigata University Medical and Dental Hospital, 1-754 Asahimachi-Dori Chuoh-Ku, Niigata, 951-8520, Japan. yu-yu117@med.niigat…. Hauptthemen laut MEDLINE: Patient Reported Outcome Measures, Neoplasms, Antineoplastic Agents, Stomatitis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

This study aimed to (1) describe longitudinal trends in patient-reported oral adverse events using the patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE) in patients receiving multidisciplinary oral care during outpatient cancer drug therapy, and (2) evaluate concordance between PRO-CTCAE and clinician-reported CTCAE scores.

Methods

Conducted at the Outpatient Cancer Chemotherapy Center, Niigata University Medical and Dental Hospital (June–December 2023), oral adverse events were assessed using PRO-CTCAE and CTCAE at baseline and every 3 weeks up to 24 weeks. Concordance for dry mouth and oral mucositis was evaluated using paired same-day scores.

Results

Among patients receiving multidisciplinary oral care, 85.2% experienced at least one oral adverse event, most commonly dry mouth. Based on PRO-CTCAE, symptoms rated as moderate or higher were reported in fewer than 10% of cases for most items. Notably, over half of patients reported persistent dry mouth of at least mild severity, and 20–30% of other symptoms also remained. These findings suggest that even lower-grade symptoms may persist and affect quality of life. Concordance between PRO-CTCAE and CTCAE was limited, with 31.1% of patients reporting greater dry mouth severity than clinicians documented.

Conclusions

Patient-reported oral adverse events, as assessed by PRO-CTCAE, were frequently mild but persistent throughout outpatient chemotherapy, suggesting a cumulative impact on quality of life. Concordance between PRO-CTCAE and clinician-reported CTCAE was limited, indicating that clinician assessments may underestimate symptoms such as dry mouth. These findings underscore the need to integrate patient-reported outcomes into routine oral care.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Patient Reported Outcome MeasuresNeoplasmsAntineoplastic AgentsStomatitisXerostomiaHumansMaleFemaleMiddle AgedLongitudinal StudiesAgedAdultAged, 80 and overSeverity of Illness Index

Stichwörter der Autor:innen

ChemotherapyConcordanceMultidisciplinary oral careOral adverse eventsOutpatient cancer treatmentPatient-reported outcomes

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Department of Pharmacy, Niigata University Medical and Dental Hospital, 1-754 Asahimachi-Dori Chuoh-Ku, Niigata, 951-8520, Japan. yu-yu117@med.niigata-u.ac.jp.
  • Department of Outpatient Cancer Chemotherapy Center, Niigata University Medical and Dental Hospital, Niigata, Japan. yu-yu117@med.niigata-u.ac.jp.
  • Department of Oral Radiology, Niigata University Medical and Dental Hospital, Niigata, Japan.
  • Department of Pharmacy, Niigata University Medical and Dental Hospital, 1-754 Asahimachi-Dori Chuoh-Ku, Niigata, 951-8520, Japan.
  • Department of Outpatient Cancer Chemotherapy Center, Niigata University Medical and Dental Hospital, Niigata, Japan.

Zitieren

APA

Sakai, Y., Katsura, K., Kanemitsu, Y., Kotake, M., & Toyama, A. (2025). Patient-reported oral adverse events during cancer chemotherapy: longitudinal evaluation using patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE) and concordance with clinician assessments. Supportive Care in Cancer. https://doi.org/10.1007/s00520-025-10126-3

Vancouver

Sakai Y, Katsura K, Kanemitsu Y, Kotake M, Toyama A. Patient-reported oral adverse events during cancer chemotherapy: longitudinal evaluation using patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE) and concordance with clinician assessments. Supportive Care in Cancer. 2025. doi:10.1007/s00520-025-10126-3

BibTeX
@article{Sakai2025,
  author = {Sakai, Yuki and Katsura, Kouji and Kanemitsu, Yoshitomi and Kotake, Masaaki and Toyama, Akira},
  title = {Patient-reported oral adverse events during cancer chemotherapy: longitudinal evaluation using patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE) and concordance with clinician assessments},
  journal = {Supportive Care in Cancer},
  year = {2025},
  doi = {10.1007/s00520-025-10126-3}
}
Kostenlos starten →